Lesson plan

TGBA01AD

TGBA01AD (also known as FKB01MD) is a serotonin reuptake inhibitor, 5-HT 1A and 5-HT 1D receptor agonist, and 5-HT 2 receptor antagonist which is under development by Fabre-Kramer for the treatment of major depressive disorder. It has been in phase II clinical trials since 2009, and as of January 2016, remains in this phase of development.

Back to article

Article summary

TGBA01AD (also known as FKB01MD) is a serotonin reuptake inhibitor, 5-HT 1A and 5-HT 1D receptor agonist, and 5-HT 2 receptor antagonist which is under development by Fabre-Kramer for the treatment of major depressive disorder. It has been in phase II clinical trials since 2009, and as of January 2016, remains in this phase of development.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.